It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-09-09T16:35:45.897Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-09-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has undertaken a public consultation on the effectiveness of the NHS prioritisation process.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "286740"} , {"_about" : "http://data.parliament.uk/resources/1142688", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142688/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-09-09T17:27:04.567Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to make the stabilisation of conditions such as cystic fibrosis part of the NICE quality of life measurement system and not just extension of life.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4368", "label" : {"_value" : "Biography information for Neil Coyle"} } , "tablingMemberConstituency" : {"_value" : "Bermondsey and Old Southwark"} , "tablingMemberPrinted" : [{"_value" : "Neil Coyle"} ], "uin" : "284175"} , {"_about" : "http://data.parliament.uk/resources/1142692", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142692/answer", "answerText" : {"_value" : "
Further to the answer the Minister of State for Care (Caroline Dinenage MP) gave on 2 April 2019 to Question 236381, that NHS England has considered this issue, and does not believe that a gap has been created as a result of the closure of Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.<\/p>
The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme.<\/p>
All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage for post stakeholder testing. These are now being progressed though the usual development process. Further information is available at the following link:<\/p>
https://www.england.nhs.uk/publication/methods-national-clinical-policies/<\/a><\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "284182"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T18:52:46.33Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 April 2019 to Question 236381, what steps NHS England has taken to fill the gap left by the closure of the Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "284181"}
, {"_about" : "http://data.parliament.uk/resources/1142693", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1142693/answer", "answerText" : {"_value" : " Further to the answer the Minister of State for Care (Caroline Dinenage MP) gave on 2 April 2019 to Question 236381, that NHS England has considered this issue, and does not believe that a gap has been created as a result of the closure of Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.<\/p> The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme.<\/p> All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage for post stakeholder testing. These are now being progressed though the usual development process. Further information is available at the following link:<\/p> https://www.england.nhs.uk/publication/methods-national-clinical-policies/<\/a><\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "284181"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T18:52:46.377Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect on treatments within NHS England\u2019s Clinical Commissioning Policy programme of the closure of the Commissioning Support Programme; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "284182"}
, {"_about" : "http://data.parliament.uk/resources/1142749", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1142749/answer", "answerText" : {"_value" : " NHS England has not yet been set the budget for products undergoing review via the NHS England prioritisation process in 2020-21.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T18:37:16.187Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what the budget is for products undergoing review via the NHS England prioritisation process in 2020-21.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "284324"}
, {"_about" : "http://data.parliament.uk/resources/1143648", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1143648/answer", "answerText" : {"_value" : " As part of a responsible Government, the Department is doing everything appropriate to prepare for European Union exit. We want to reassure patients that we should be fully prepared for leaving on 31 October, and that our plans should ensure the supply of medicines and medical products remains uninterrupted when we leave the EU.<\/p> The Department is implementing a multi-layered approach, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. This should ensure the continuity of supply of medicines and medical products following EU exit.<\/p> We continue to engage with stakeholders and update our communications regularly. We are looking to update Members shortly.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-05T16:37:54.86Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential effect on the supply chains for medicines and medical supplies of the UK leaving the EU without a deal; what steps he is taking to protect ongoing supplies of medicines and medical supplies; and if he will update the dear colleague letter of the 27 June 2019 entitled No deal Brexit contingency planning assumptions for continuity of supply of medicines and medical products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4506", "label" : {"_value" : "Biography information for Antoinette Sandbach"}
}
, "tablingMemberConstituency" : {"_value" : "Eddisbury"}
, "tablingMemberPrinted" : [{"_value" : "Antoinette Sandbach"}
], "uin" : "285138"}
, {"_about" : "http://data.parliament.uk/resources/1143719", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1143719/answer", "answerText" : {"_value" : " As part of a responsible Government, the Department is doing everything appropriate to prepare for European Union exit. We want to reassure patients that our plans should ensure the supply of medicines and medical products remains uninterrupted when we leave the EU on 31 October.<\/p> The Department is implementing a multi-layered approach, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T19:00:53.243Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans the Government has to maintain medical and drug supplies to the UK in the event that the UK leaves the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4469", "label" : {"_value" : "Biography information for Angela Crawley"}
}
, "tablingMemberConstituency" : {"_value" : "Lanark and Hamilton East"}
, "tablingMemberPrinted" : [{"_value" : "Angela Crawley"}
], "uin" : "285347"}
, {"_about" : "http://data.parliament.uk/resources/1139933", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139933/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence has advised that the highly specialised technologies (HST) programme has, to date, only needed to assess single products for single indications. Should a situation arise for the evaluation of multiple technologies for the same indication within the HST process, the feasibility and suitability of this would be considered at that point. Any such process would closely reflect the established multiple technology appraisal process, which is designed to appraise more than one technology.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-22T15:38:13.043Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether NICE\u2019s multiple technology appraisal process can be applied to treatments evaluated through NICE\u2019s highly specialised technologies appraisal programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "278512"}
, {"_about" : "http://data.parliament.uk/resources/1139369", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139369/answer", "answerText" : {"_value" : " NHS England does not believe that the closure of the Commissioning Support Programme will leave a gap in the review of treatments.<\/p> The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme, undertaken by the National Institute for Health and Care Excellence (NICE), except where there is a clear rationale not to do so. NICE expects to implement this expansion from April 2020. It will be in a position to start progressing topics through the NICE topic selection process from the summer of 2019.<\/p> All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage as for all topics, post stakeholder testing. These are now being progressed though the usual development process. This process is set out in \u2018Methods: National Clinical Policies\u2019 at the following link:<\/p>